CompletedPhase 1NCT05882695

Study of SPG302 in Healthy Volunteers and ALS Participants

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Spinogenix
Principal Investigator
Ofer M Gonen, MD
Nucleus Network (for healthy volunteers)
Intervention
SPG302(drug)
Enrollment
88 enrolled
Eligibility
18-55 years · All sexes
Timeline
20232025

Study locations (4)

Collaborators

Novotech (Australia) Pty Limited

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05882695 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials